Tag: Immunotherapy
NHLBI Updates Guidance for Management of Asthma
Guidance focuses on tailored treatment interventions for specific age groups based on disease severity
Dexamethasone May Hinder Immunotherapy for Glioblastoma
Findings seen in preclinical studies of mice, survival data from patients receiving PD-(L)1 blockade for GBM
AI Model May Predict Immunotherapy Response in Melanoma
Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma
Immunotherapy Combo Treats Advanced Kidney Cancer
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib
Infection Risk Up in Month After CAR T-Cell Immunotherapy
Infection rates increase in patients with ALL aged ≤26 years in first month, then decrease at days 29 to 90
SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression-free survival
FDA Labeling Restriction Quickly Reflected in Oncology Practice
FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
But not for corticosteroid-free clinical remission; also, ustekinumab superior to placebo
Electronic Nose Analysis May Predict Response to Anti-PD-1 Therapy in NSCLC
Initial breath analysis predicts individual treatment response to anti-PD-1 therapy at three months
Allergy Immunotherapy May Decrease Asthma Progression
Findings strongest for youngest patients with incident asthma treated in routine care
